Ignite Creation Date:
2025-12-26 @ 11:00 AM
Ignite Modification Date:
2025-12-31 @ 11:36 AM
Study NCT ID:
NCT04333706
Status:
RECRUITING
Last Update Posted:
2025-04-17
First Post:
2020-04-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Sponsor:
University of Southern California
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-26
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-04-01
First Submit QC Date:
None
Study First Post Date:
2020-04-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-16
Last Update Post Date:
2025-04-17
Last Update Post Date Type:
ACTUAL